GlassScriptPhysician profile
Tamara Siemer
NPI 1679799191
$4,120.87
in general payments reported to CMS, 2019-2025
25 companies · $878 in 2025
The $878 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $348 · 2022: $951 · 2023: $1,117 · 2024: $828 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,822.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $472.48 | 2022-2024 | Lokelma, Breztri, Airsupra |
| Vertos Medical, INC. | $391.67 | 2024 | Mild Device Kit |
| Edwards Lifesciences Corporation | $292.64 | 2021-2025 | Sapien 3 Ultra Resilia |
| Biotronik Nro, INC. | $267.55 | 2025 | Prospera |
| Gilead Sciences, INC. | $217.02 | 2022-2023 | Descovy |
| Novo Nordisk INC | $208.20 | 2023-2025 | Wegovy |
| Axsome Therapeutics, INC. | $188.07 | 2023 | Auvelity, Sunosi |
| Idorsia Pharmaceuticals US INC | $159.52 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Evoke Pharma, INC. | $125.00 | 2023 | Gimoti |
| Aimmune Therapeutics, INC. | $123.97 | 2025 | Zenpep |
| Alexion Pharmaceuticals, INC. | $121.65 | 2024 | Ultomiris |
| Ani Pharmaceuticals, INC. | $121.61 | 2023 | Purified Cortrophin Gel |
| Lilly USA, LLC | $120.83 | 2022 | |
| Esperion Therapeutics, INC. | $119.20 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $118.77 | 2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $116.30 | 2025 | |
| Neurocrine Biosciences, INC. | $115.02 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.48 | 2022 | |
| Abiomed | $112.17 | 2022 | |
| Abbvie INC. | $109.98 | 2024 | |
| Medtronic, INC. | $101.45 | 2021 | |
| Sage Therapeutics, LLC | $100.00 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $91.95 | 2023 | |
| Sanofi-Aventis U.S. LLC | $86.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Siemer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.